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( I ) The constituents of the C R G can be limited to biologically safe ionic species such as Na+, Ca2+ and PO:-.
(2) The release system is completely soluble in water and no residue remains.
(3) There is no evidence of any mechanism for biodegradation of the CRG and so one possible cause of premature or accelerated release is eliminated.
(4) The absolute release rate can be selected anywhere in a spectrum covering several orders of magnitude and the ratecontrolling process has zero-order kinetics.
(5) The release rate can be selected to be pH-sensitive or pH-independent.
(6) Complex temporal release-rate patterns can be obtained readily by the choice of geometrical shape or composition profile of the device.
(7) The controlled release of organics or other heatsensitive materials which cannot be incorporated in the glass can be realized by the use of composite structures in which the CRG is the rate-controlling constituent.
(8) A number of different functions can be performed by a single CRG-based device. For example, C R G can be used as a biomedical resorbable material in surgery and the C R G structural component can release an AM as it dissolves. Similarly the CRG of the sinter-composite used for organic AM release can itself release any selected inorganic adjuvant.
(9) CRG boluses containing either copper or cobalt and weighing approx. either 70g or 15g, have been administered to both cattle and sheep. More than 90% of the boluses remained either in the reticulum or rumen for up to 270 days after dosing. The rates of release of trace element remained virtually linear and the boluses did not become covered with an insoluble coating. The copper boluses provided more than 2mg of Cu/day for sheep and 8mg/day for cattle and increased the liver copper stores of both species. The cobalt boluses provided more than 0.15 mg of Co/day for sheep and more than 0.85mg/day for cattle. The concentrations of vitamin B,,* in the liver and plasma of treated sheep increased significantly.
Generally, high molecular weight pharmaceuticals, such as polypeptides, are not effective by the oral route of administration and so consequently they are usually administered parenterally, Since such drugs often have very short half-lives frequent injections are required to produce an effective therapy. The most practical and effective dosage form for polypeptides would therefore be one which would release the drug continuously at a controlled rate over a period of weeks or even months; preferably the formulation should be biodegradable and so disappear completely from the site of injection. The advent of genetic engineering and the consequent production of large quantities of biologically interesting peptides, and the chemical synthesis of clinically useful peptides such as Until recently such a sustained-release polypeptide formulation was no more than an idle dream since the methodology required to generate it, by using pharmaceutically acceptable procedures and materials, was not known. A number of major problems had to be recognized and resolved. Firstly, the mechanism most commonly used to achieve sustained release, namely controlled diffusion through a matrix or membrane, may not be appropriate for a high molecular weight polypeptide (Baker & Lonsdale, 1974) . Design of a sustained-release dosage form must take into account both the properties of the rate-controlling polymer and the drug. For diffusion of the drug through the polymer to occur it must have some limited solubility in the polymer; this is often the case with low molecular weight drugs. In contrast it is well established that, in the absence of specific interactions, polypeptides will be either insoluble in, or incompatible with, any polymer such as a polyester, which has a totally dissimilar structure, because of entropic and enthalpic factors. Consequently, low or negligible solubility of the macromolecular drug in a polymer, such as a polyester, will prevent diffusional transport of the agent through the polymer. With regard to the properties of the drug the most important of these are its size, shape and solubility. There is an approximate log-log correlation between molecular weight (M) and diffusion coefficient log D = a -b log M where a and b are arbitrary constants such that D decreases as the molecular weight of the drug increases (Baker & Lonsdale, 1974) . For polypeptides M is large and the diffusion coefficient becomes vanishingly small because the diffusant cannot be accommodated by the free volume of polymer arising from translational segmental movement. Consequently polymers, such as polyesters, are not likely to allow partition-dependent diffusion of polypeptides to occur.
Secondly, peptides are biologically labile and can be readily degraded by tissue enzymes. They must, therefore, be effectively protected at the depot site if active drug is to be released continuously. The difficulty of achieving this is emphasized by the fact that synthetic polypeptides have actually been used as biodegradable carriers for drugs such as steroids (Mitra et al., 1979) and narcotic antagonists (Sidman et al., 1981) .
Thirdly, excipients used to achieve sustained release might provoke an adjuvant-induced immunological response, which may be related to the nature of the excipient, the delivery rate, or the profile of release. Finally, longlasting depots might become encapsulated by fibrous tissue, thus inhibiting release of the drug. This is certainly the case for silicone implants.
Probably because of these imposing problems the use of polyesters as the slow-release carriers for water-soluble, biologically labile polypeptides has received only cursory evaluation. This paper describes the development of biodegradable delivery systems based on polyesters such as poly(d,l-lactide) and poly(d.1-lactide-co-glycolide) which give continuous release of polypeptides over an extended period of time. Although emphasis is focused on the LH-RH analogue, Zoladex, it has been shown that the technology can also be applied to higher molecular weight polypeptides, such as mouse epidermal growth factor and bovine prolactin.
Preparation of polymers Biodegradable polymers were prepared at 160°C by the ring-opening polymerization of dry, freshly prepared acid dimers. d.1-lactide and glycolide, by using organo-tin compounds as catalysts. Control of molecular weight was achieved by using a chain-transfer agent such as d.1-lactic acid. In this way polymers of variable composition, having intrinsic viscosities in chloroform at 25°C ranging from -0.1 to > I , can be prepared. The polymers were characterized by gel-permeation chromatography relative to polystyrene standards to define number average molecular weight ( M J , weight average molecular weight ( M , ) and polydispersity ( M N / M n ) , and additionally by I3C n.m.r. to define the distribution of co-monomers.
Degradation studies
Because polypeptides have high molecular weights and are water soluble their release from these polyesters by classical partition-dependent diffusion is unlikely to occur. Consequently, degradation of the polymer will be a critical factor in determining transport of the high molecular weight polypeptide from the dosage form. Therefore the degradation of these polymers in the absence of drug has been characterized in terms of molecular weight and its distribu-
tion, weight loss, water uptake and morphology of the hydrated and degraded polymer.
Degradation of the polymer at 37°C in aqueous McIIvaines buffer, pH 7.4 (Scientific Tables, Documenta Geigy, 1970) results in progressive changes in molecular weight distribution. The profile of weight loss from the degrading polymer is consistent with bulk hydrolysis of the polyester arising from hydrolytic scission of ester groups. As the molecular weight of the degrading polymer falls it becomes increasingly more hydrophilic and so shows enhanced water uptake. This water uptake is further influenced by the geometry of the degrading polymer. Furthermore, degradation is dependent on molecular weight, composition and structure of the polyester and ultimately results in generation of microporosity in the degrading matrix.
These studies suggest that water-soluble polypeptides may be released from poly(d,l-lactide-co-glycolide) and poly(d.1-lactide) since the degradation of these polyesters is characterized by the generation of microporosity and enhanced water uptake. Both of these processes should facilitate transport of polypeptide from the dosage form as this is likely to involve diffusion through aqueous pores generated in the drug/polymer matrix.
In this event the release of polypeptide will differ mechanistically from those processes thought to occur during release of steroids, narcotic antagonists and antimalarials from poly(d,l-lactide-co-glycolide) and poly(d.1-lactide) ( mammary and prostate tumours. Because of low oral potency the drugs have been usually administered parenterally once or more times daily. A biodegradable formulation, either as a subdermal depot or an injectable suspension, which will deliver the drug over a period of 28 days, would be more clinically acceptable. Research was focused on release of Zoladex (molecular weight 1269) from implants because this was thought more likely to afford a clearer understanding of the physicochemical parameters which allow transport of drug from the dosage form. In this respect, Zoladex is a particularly useful drug as studies both in vitro and in vivo can be undertaken. In the situation in vitro desorption of the drug into an external aqueous medium can be measured by high-performance liquid chromatographic analysis of the aqueous phase to give a quantitative measure of the amount released.
Continuous release of the polypeptide in viuo can be measured qualitatively by the biological effect elicited in regularly cycling, adult female rats. Normally these rats have an oestrous cycle of 4 or 5 days and the occurrence of oestrus is indicted by the presence of cornified cells in vaginal smears. In rats given subdermal depots of Zoladex, release of drug at an effective rate will cause a fall in circulating oestrogens which, in turn, leads to a suppression of oestrus and the absence of cornified smears. The rats will, therefore, show an extended period of dioestrus.
Transport of drug from these depots is governed by various properties of the rate-controlling polyester. These properties include polymer composition, molecular weight and molecular weight distribution of the polymer, level of drug incorporation, morphology of the drug/polymer mixture, degradation characteristics of the polymer, and geometry.
I t has been shown that release of polypeptide from these
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biodegradable polyesters occurs by diffusion of drug through aqueous pores generated in the dosage form. These aqueous channels, which facilitate drug release, are generated by two distinct and separate mechanisms. The first involves leaching of drug from polypeptide domains at or near the surface of the delivery system. However, drug within the body of the implant, existing in isolated domains not continuous or contiguous with the surface, cannot be released until the second mechanism becomes operative. This second mechanism involves degradation of the polyester and is associated with generation of microporosity in the degrading polymer and enhanced water uptake. This generation of porosity allows an aqueous diffusion path to be established for the drug within the delivery system and so further transport of drug can occur. Parameters controlling the initial phase of release are, for example, drug loading and geometry, whereas the second phase of release is intrinsically related to the degradation properties of the polyester. The degradation profile of the polymer is dependent on molecular weight and distribution, rate of water uptake and polymer composition (proportions of d.1-lactide and glycolide).
When these two phases of release do not overlap a biphasic release pattern is observed both in vitro (Fig. la) and in vivo (Fig. 2a) . However, continuous release of the peptide can be achieved by extending the initial release phase so that it overlaps with the degradation phase of release or by ensuring that degradation commences almost immediately (Fig. lb) . By controlling the properties of the polyester, depots have been defined which give continuous release of Zoladex over at least 28 days both in vitro (Fig. lb) and in vivo (Fig. 2b) . These depots have been used to induce a castration-like effect in rats and thereby to inhibit growth of mammary and prostate tumours. Fig. 3 shows the effect of a single subcutaneous depot containing 500pg of Zoladex on the growth of rat dimethylbenzanthranene-induced, mammary tumours (Jordan, 1982) . In control animals given placebo depots, tumours have doubled in size within 4 weeks. Tumours regress markedly in rats given a depot containing Zoladex, to an extent similar to that observed previously after daily subcutaneous injections of the drug (Furr & Nicholson, 1982) . If rats are given single subcutaneous depots at the start of the study and at weeks 4 and 8, a far more profound regression occurs (Fig. 4) . By week 11 none of the tumours present at the start of the study is palpable. As the effect of the final depot wears off, around week 16, recovery in the growth of the tumours occurs. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I   0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 Treatment groups are placebocontrols h; 13 rats); Zoladex (0 ; I2 rats) and surgically castrated animals (0 ; 13 rats).
Single depots of I mg of Zoladex given every 28 days to rats bearing hormone-responsive, Dunning R3327, transplantable prostate tumours (Jordan, 1982) similarly cause a marked inhibition of tumour growth to values indistinguishable from those in castrate animals (Fig. 5) .
These results indicate that sustained-release depot formulations of peptides can be produced which will be more clinically acceptable than daily aqueous injections. Although this paper concentrates on the delivery of the LH-RH analogue Zoladex, we have shown that the technology can be successfully applied to other peptides with a range of molecular weights, namely tetragastrin, epidermal growth factor and bovine prolactin (European Patent Application no. 82300416, Publication no. 58481 .) Application of this technology could markedly alter attitudes to the potential of peptides as drugs, and is particularly timely since parallel developments in genetic engineering are likely to lead to the wide availability of biologically interesting peptides.
